
usd jan pm et
summari compani develop da vinci surgic system use advanc robot
computer visual technolog minimally-invas surgeri
price-to-earnings oper ep
earli mover field robot surgeri
establish competit technolog
domin market expect compani
face intens competit soon think
margin risk compani abil continu
on-going concern minim given high switch
cost robot surgeri platform expect
loyal custom industri
also typic maintain net cash posit
achiev posit free cash flow risk could threaten
busi includ obsolesc regulatori
ep estim base cfra oper earn histor
earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan pm stock trade
expect sale growth
oper leas
arrang increas trade-in activ
level addit
pull forward system placement china
custom expedit
purchas cycl avoid anticip tariff
anticip procedur volum
growth
procedur growth like driven
sustain grow adopt robot
gener surgeri particularli colorect
bariatr thorac hernia repair procedur
isrg grow exposur outsid
expect isrg oper margin declin
firm continu invest
heavili support new product ou market
develop adopt robot
gener surgeri isrg increas spend
new improv technolog crucial
minim compani market share loss
incom competit expect increas
price negoti elong negoti
timelin isrg competitor get closer
launch robot surgeri offer
find share current trade
ep estim vs
rang
fair valu domin
forc gener robot surgeri space sinc
compani incept howev expect
return invest capit
erod compani increas spend
maintain domin market posit
face incom and/or mount competit
formid behemoth medtron
johnson johnson
addit plethora smaller competitor
despit evid begin
declin invest cost increas
compani still trade forward price-to-earnings
substanti level seen sever year
ago lead us believ share
overvalu
risk rate target includ
pressur strong perform new
target price assum
multipl next ep
estim peer
domin market share high profit
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview intuit surgic design da vinci surgic system product
incorpor advanc robot computer visual technolog improv abil
surgeon perform complex minimally-invas procedur end compani
instal base da vinci surgic system end end
surgeon use compani technolog complet estim
surgic procedur variou type includ urolog gynecolog cardiothorac gener surgeri
surgic procedur
commerci four gener da vinci surgic system fourth gener includ
da vinci sp da vinci da vinci xi da vinci surgic system consist surgeon consol
patient-sid cart high-perform vision system proprietari wrist instrument system
translat surgeon natur hand movement instrument control consol correspond
micro-mov instrument posit insid patient small punctur incis port
system aim give surgeon intuit control rang motion fine tissu manipul capabl
visual characterist open surgeri simultan allow use small port
goal improv surgeri maxim number patient deriv benefit
competit environ although pioneer leader robotic-assist surgeri
face continu face competit form exist open surgeri convent
minim invas surgeri drug therapi radiat treatment emerg intervent surgic
approach success depend continu clinic technic innov qualiti reliabl
well educ hospit surgeon patient demonstr result associ da
vinci surgeri valu rel techniqu recent year numer compani
introduc product field robot surgeri made explicit intent enter field
robot surgeri verb surgic appear spend heavili
anticip incom competit
decemb ownership exclus field-of-us licens
foreign patent foreign patent applic manufactur
market use class ii medic devic da vinci system govern extens
regul administ food drug administr think act signific barrier
entri competitor
da vinci system expens averag sell price exclud oper leas leas buyout
million million system also take signific train
time surgeon becom accustom result switch cost high sinc
earli mover robotic-assist surgeri high switch cost present anoth barrier entri
financi trend revenu account total revenu total revenu
billion higher prior year five-year compound annual growth rate
compound-annual-growth-rate adjust earn per share ep vs five-year compound-annual-growth-rate
adjust ep free cash flow defin cash flow oper
less capit expenditur posit least past five year free cash flow million
addit compani typic maintain net cash posit compani invest substanti
amount research develop expens revenu
significantli higher preced five-year averag expect compani continu
focu effort internally-gener innov maintain technolog lead rather
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc septemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neutral expect
compani continu achiev robust organ
growth mid- high-single-digit revenu
growth driven new product
data provid estim world-wide medic
devic sale grow
time think potenti slowdown
macroeconom growth could pressur
industri driver yet sub-industri
includ mani product area
histor recession-resist
equip use non-elect procedur
gener see posit long-term
fundament medic devic manufactur
includ increas global demand
popul rise outlay
result steadi flow innov product
revenu growth
polit regulatori perspect
medic devic industri larg avoid
scrutini unlik area health
drug maker fact medic devic tax
final repeal decemb remov
signific risk sale devic maker
think industri continu
dwindl industri come back
favor especi sinc valuat health
rel
forward price-to-earn basi think
higher valuat sub-industri
mostli warrant margin expans
revenu growth opportun associ
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much
commentari around introduct mdr
reason believ new
regul could neg impact
industri exampl juli
submit letter world trade
organ request mdr ivdr
delay three year also novemb
associ critic slow piecem
implement new regulatori
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
expect industri earn rise
low-double-digit percentag driven sale
new product command higher
margin project industri oper
ebit margin
estim margin
 health equip
valu composit index
 health equip
sub-index rose vs declin
base index
five-year market price perform jan
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra maintain sell opinion share
inc lower target reflect multipl
slightli isrg averag ep
estim ep vs exceed expect
due stronger-than-expect sale growth margin lower ep
initi ep sale grew
yoy million procedur grew global averag sell
price asp da vinci machin increas million
million prior-year period result exceed expect due
pull forward system placement china custom like expedit
purchas cycl avoid anticip tariff increas previou
note highlight isrg recent inventori level still
elev could neg impact margin earn call guid
adjust gross margin consensu expect
margin /kevin huang cfa
et cfra keep hold opinion share inc
lower target above-p
multipl ep estim ep vs
lower estim higher-than-expect
oper expens manag previous warn oper
expens would high support newli launch platform
strengthen comput capabl invest project support
futur scale lower ep ep
sale increas million driven increas
world-wide da vinci procedur global averag sell price da vinci
system declin million million million
declin reflect trade-in transact sale vs
volume-bas incent multipl system purchas greater
proport da vinci system higher proport distributor sale /kevin
et cfra keep sell opinion share inc
lift target reflect multipl
slightli averag ep
estim ep vs substanti beat
consensu expect driven much stronger expect sale
sale grew yoy million da vinci averag sell price
asp increas contrari expect million million
million asp increas driven favor
product mix higher volum direct sale lift ep
ep
transpar recent inventori build believ increas
could neg impact margin line also comment
colorect indic da vinci sp latest gener product would
requir clinic trial mean indic sp
unlik /kevin huang cfa
et cfra maintain hold opinion share
inc lower target above-p
multipl ep estim ep
vs lower estim lower ep
initi ep lower ep
expect increas oper expens
compani acceler invest china increas suppli capac
informat launch new platform expect largest portion
spend go china unlik see immedi
result quota surgic robot tariff
system ship sale increas million
growth gener surgeri world-wide urolog procedur
ship da vinci surgic system quarter compar
prior-year period /kevin huang cfa
pm et cfra cut opinion share inc sell
hold lower target base
forward price-to-earnings multipl averag ep
estim domin forc gener robot
surgeri space sinc incept compani trade
averag forward price-to-earnings past year significantli
roughli averag similarli size med-tech compani yet expect
return invest capit erod compani increas
spend maintain domin market posit face incom and/or
mount competit formid behemoth
johnson johnson addit plethora smaller
competitor despit evid begin declin
invest cost increas compani still trade forward price-to-earnings
substanti level seen sever year ago lead us believ
share overvalu /kevin huang cfa
et cfra maintain hold opinion share
inc lift target above-p
multipl ep estim ep vs
significantli exceed consensu expect due
revers unfavor mix prior quarter result rebound
averag sell price asp da vinci machin million
million million benefit
quarter elev leas buy-out revenu million
million million respect lift
ep lower ep
sale grew impress billion driven higher
higher system placement moder growth hernia
colorect procedur key gener surgeri growth driver driven
competit system access busi surgeri center grow
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
